|United Therapeutics Corporation|
1040 Spring Street
United States - Map
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening conditions worldwide. Its lead product comprises Remodulin, an injection used for the treatment of pulmonary arterial hypertension (PAH). The company also provides Tyvaso, an inhaled prostacyclin therapy; and Adcirca, a once-daily oral therapy for the treatment of PAH. In addition, it develops Orenitram, a prostacyclin analog for treatment of PAH; Ch14.18 MAb, an antibody for the treatment of neuroblastoma; Beraprost 314d, which is under Phase III clinical trials for the treatment of PAH; and PLacental eXpanded cells that are under Phase I trial for the treatment of PAH. Further, the company is involved in the pre-clinical stage development of glycobiology antiviral agents for the treatment of infectious diseases; UV-4B, an antiviral alpha-glucosidase inhibitor for the treatment of dengue; and engineered lungs and lung tissue that can be transplanted into patients suffering from PAH and other lung diseases. United Therapeutics Corporation was founded in 1996 and is headquartered in Silver Spring, Maryland.
|United Therapeutics Corporation’s ISS Governance QuickScore as of Dec 1, 2014 is 10. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 10; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Dr. Martine A. Rothblatt Ph.D., MBA, J.D.,
Founder, Chairman and Chief Exec. Officer
|Dr. Roger A. Jeffs Ph.D.,
Pres, Chief Operating Officer and Director
|Mr. John M. Ferrari ,
Chief Financial Officer, Principal Accounting Officer and Treasurer
|Mr. Paul A. Mahon J.D.,
Exec. VP of Strategic Planning, Gen. Counsel and Corp. Sec.
|Dr. Martin D. Auster M.D.,
VP of Bus. Devel.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|